维西医结合治疗异常粘液质型良性前列腺增生症疗效观察

发布时间：2018-05-08 18:38

本文选题：维西医结合 + 异常粘液质　；参考：《新疆医科大学》2017年硕士论文

【摘要】：目的:本课题通过研究维西医结合疗法对异常粘液质型良性前列腺增生症患者的国际前列腺症状评分IPSS(International Prognostic Scoring System)、生活质量评分QOL(Quality of Life)、血清PSA浓度与超声学参数的影响,探讨维吾尔医综合疗法结合西医在治疗BPH的影响,为异常粘液质型良性前列腺增生症的维吾尔医治疗提供进一步明确的理论支持。方法:所有病例均为新疆维吾尔自治区维吾尔医医院外科自2016年1月至2017年1月的住院确诊异常粘液质型良性前列腺增生症患者124例,以上患者年龄46~85岁,中位年龄60.5岁(P25=55岁,P75=65岁)。符合纳入标准的120例患者,采用非随机对照试验方法分入治疗组(盐酸坦索罗辛缓释胶囊口服加用维吾尔医综合疗法)和对照组(盐酸坦索罗辛缓释胶囊口服),每组60例。治疗21天,观察异常粘液质型良性前列腺增生患者治疗前后IPSS评分、QOL评分、血清PSA(prostate-specific antigen)浓度、残余尿量(RU)、前列腺体积的影响比较。结果:治疗后2组患者综合疗效、IPSS评分、QOL评分、残余尿量(RU)等指标均明显改善,与治疗前比较,差异均有显著性意义(P0.05);治疗后两组患者前列腺体积、血清PSA浓度等指标均无明显改变,与治疗前比较,差异均无显著性意义(P0.05);治疗后两组患者不良反应比较,差异有统计学意(P0.05)。结论:本观察结果表明,使用维吾尔医综合疗法结合盐酸坦索罗辛缓释胶囊口服可明显缓解异常粘液质型BPH患者临床症状,并可以明显改善IPSS评分、QOL评分、残余尿量(RU)等指标,在改善症状和提高患者生活质量方面与盐酸坦索罗辛缓释胶囊单独口服比较有一定的优势。维西医结合治疗异常粘液质型良性前列腺增生症效果明显,不良反应少,值得推广应用。
[Abstract]:Objective: the purpose of this study was to study the effects of combined therapy with western medicine on international prostate symptom score (IPSS(International Prognostic Scoring system), quality of life score (QOL(Quality of life), serum PSA concentration and ultrasonic parameters in patients with abnormal mucous benign prostatic hyperplasia (BPH). To explore the effect of Uygur medicine combined with western medicine in the treatment of BPH, and to provide further theoretical support for Uygur medical treatment of abnormal mucous type benign prostatic hyperplasia (BPH). Methods: all the patients were 124 patients with abnormal mucous type benign prostatic hyperplasia diagnosed from January 2016 to January 2017 in surgery department of Uygur Medical Hospital of Xinjiang Uygur Autonomous region. The age of the above patients was 460-85 years old. The median age was 60.5 years (P 2555) and 65 years (P 75). 120 patients who met the inclusion criteria were divided into treatment group (Tansoroxine hydrochloride sustained release capsule orally combined with Uygur medicine comprehensive therapy) and control group (tansoloxin hydrochloride sustained release capsule orally, 60 cases in each group). After 21 days of treatment, the effects of IPSS score, serum PSA(prostate-specific antigen-concentration, residual urine volume and prostate volume on the patients with abnormal mucous type benign prostatic hyperplasia (BPH) were compared before and after treatment. Results: after treatment, the indexes of IPSS score, QOL score and residual urine volume (RUU) were significantly improved in both groups, and there were significant differences between the two groups before and after treatment (P 0.05). There was no significant change in serum PSA concentration, and there was no significant difference between the two groups before and after treatment, and there was a significant difference in adverse reactions between the two groups after treatment (P 0.05). Conclusion: the results showed that the combination of Uygur medicine combined with tansoloxine hydrochloride sustained release capsule could significantly relieve the clinical symptoms of patients with abnormal mucous type BPH, and improve the IPSS score and residual urine volume (RUU). There are some advantages in improving symptoms and quality of life of patients compared with tansoloxine hydrochloride sustained-release capsules alone. The treatment of abnormal mucous type benign prostatic hyperplasia with combination of Weiwei and western medicine has obvious effect and less adverse reaction, so it is worth popularizing and applying.
【学位授予单位】：新疆医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R29

【参考文献】